menu
    • menu
    [{"orgOrder":0,"company":"Autotelic Bio","sponsor":"Oncotelic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Autotelic Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Autotelic Bio \/ Oncotelic","highestDevelopmentStatusID":"1","companyTruncated":"Autotelic Bio \/ Oncotelic"},{"orgOrder":0,"company":"Autotelic Bio","sponsor":"Oncotelic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Autotelic Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Autotelic Bio \/ Oncotelic Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Autotelic Bio \/ Oncotelic Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Autotelic Bio

    Menu

    Autotelic Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Autotelic Bio

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Autotelic Bio

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apomorphine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Oncotelic Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Oncotelic Acquires Fast to Market Late-Stage Drug Candidate for Parkinson Disease, Erectile Dysfunction, and F...

                            Details : The acquisition of AL-101 brings in a product with a substantially large market potential for existing and unmet medical needs into the Company. AL-101 has shown a safety and efficacy profile and is phase 3 ready with 6 clinical trials completed and ove...

                            Brand Name : AL-101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 04, 2021

                            Lead Product(s) : Apomorphine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Oncotelic Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Autotelic Bio

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Autotelic Bio

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apomorphine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Oncotelic Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Oncotelic to Acquire Late-Stage Drug Candidate for Parkinson Disease, Erectile Dysfunction, and Female Sexual ...

                            Details : The acquisition of AL-101 (intranasal apomorphine), expands Oncotelic's product portfolio. AL-101 will also be developed as a new drug against Female Sexual Dysfunction ("FSD"), including Hypoactive Sexual Desire Disorder ("HSDD").

                            Brand Name : AL-101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 01, 2021

                            Lead Product(s) : Apomorphine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Oncotelic Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth